**S6 Table. Risk of bias assessment**

| Author-year | Randomisation | Allocation concealment | Blinding[a] | Bias related to participants included |
|---|---|---|---|---|
| Hasugian-2007 [26] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Ratcliff-2007 [27] | Yes | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Karunajeewa-2008 [6] | Yes | Block randomisation by site | No | Low risk[b] |
| Awab-2010 [39] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Phyo-2011 [28] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Abdallah-2012 [40] | No | N/A | No | Moderate risk – data for 5/43 patients that were lost to follow up were not available |
| Barber-2013 [29] | No | N/A | No | Low risk[b] |
| Hwang-2013 [41] | Yes - but only one treatment arm included | Randomisation centrally; sealed envelopes | No | Low risk[b] |
| Pasaribu-2013 [30] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Sutanto-2013 [31] | Yes | Block randomisation centrally; opaque sealed envelopes | No | Low risk – data for 1/116 patients that withdrew consent prior to treatment was unavailable |
| Laman-2014 [32] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Lidia-2015 [33] | No | N/A | No | Low risk[b] |
| Nelwan-2015 [34] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Thuan-2016 [35] | Yes - but only one treatment arm included | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Abreha-2017 [42] | Yes | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Chu-2018 [36] | Yes | Block randomisation centrally | No | Low risk[b] |
| Grigg-2018 [37] | No | N/A | No | Low risk[b] |
| Daher-2018 [4] | Yes | Block randomisation centrally; opaque sealed envelopes | No | Low risk[b] |
| Poespoprodjo-2018 [38] | No | N/A | No | Low risk[b] |

[a]Blinding refers to the blinding of the patient and clinician to treatment.

[b]All individual patient data available and curated and standardised with re-analysis according to the WWARN Data Management and Statistical Analysis plan [17].

Bias related to assessment of outcomes was considered to be low risk as studies were efficacy studies with recurrent parasitaemia as their primary outcomes, consistent with the outcome of the current meta-analysis; Bias related to time to event outcome data has been minimised in the current analysis by extending analysis beyond day 42 where possible.